Photo credit: Freepik

Elon Musk's Neuralink has received approval to conduct its first clinical trial in Canada for a device designed to enable paralyzed individuals to use digital devices through thought alone.

This groundbreaking brain chip aims to assess the safety and initial functionality of its implant, allowing people with quadriplegia to control external devices mentally.

The University Health Network hospital in Toronto has been selected to perform the complex neurosurgical procedure, marking a significant milestone for Neuralink.

In the U.S., the company has already implanted the device in two patients.

According to Neuralink, the second trial patient has successfully used the device to play video games and learn 3D object design.

READ MORE: Elon Musk adds Microsoft to OpenAI lawsuit

Founded in 2016 by Elon Musk and a team of engineers, Neuralink is also developing a brain chip interface that can be implanted within the skull.

This technology promises to help disabled patients regain movement, communication abilities, and even restore vision.

In September, Neuralink received the U.S. Food and Drug Administration's "breakthrough device" designation for its experimental implant aimed at restoring vision.

‍